-
1 Comment
Albert David Limited is currently in a long term uptrend where the price is trading 15.4% above its 200 day moving average.
From a valuation standpoint, the stock is 81.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.9.
Albert David Limited's total revenue sank by 17.9% to $653M since the same quarter in the previous year.
Its net income has increased by 16.5% to $61M since the same quarter in the previous year.
Finally, its free cash flow fell by 0.0% to $115M since the same quarter in the previous year.
Based on the above factors, Albert David Limited gets an overall score of 3/5.
| Exchange | NSE |
|---|---|
| CurrencyCode | INR |
| ISIN | INE155C01010 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Beta | -0.04 |
|---|---|
| Market Cap | 5B |
| PE Ratio | 11.66 |
| Target Price | None |
| Dividend Yield | 0.6% |
Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs in India. It offers formulations for parenterals, oral/enteral, topical agents, and vision care products. The company exports its products to Latin American, Southeast Asian, and other African countries. Albert David Limited was incorporated in 1938 and is headquartered in Kolkata, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ALBERTDAVD.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
